You have 9 free searches left this month | for more free features.

ensartinib

Showing 1 - 13 of 13

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Ensartinib
  • Beijing, Beijing, China
    Department of Respiratory and Critical Care Medicine, Peking Uni
Aug 10, 2022

Non Small Cell Lung Cancer Trial in Beijing (Ensartinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Ensartinib
  • Beijing, Beijing, China
  • +1 more
Aug 17, 2022

Solid Tumor, NSCLC Metastatic Trial in Guanzhou (Ensartinib)

Recruiting
  • Solid Tumor
  • Non-Small Cell Lung Cancer Metastatic
  • Ensartinib
  • Guanzhou, Guangdong, China
    Sun yat-sen Univerisity Cancer Center
Nov 22, 2021

Melanoma Trial in United States (Ensartinib, ALKATI by Customized Nanostring Assay)

Active, not recruiting
  • Melanoma
  • Ensartinib
  • ALKATI by Customized Nanostring Assay
  • Middletown, New Jersey
  • +3 more
Jan 25, 2022

NSCLC Trial in Tianjin (Ensartinib, Placebo)

Recruiting
  • Non-small Cell Lung Cancer
  • Ensartinib
  • Placebo
  • Tianjin, China
    TianJin Medical University Cancer Institute & Hospital
Jul 13, 2022

NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)

Available
  • Non-Small Cell Lung Cancer
  • ALK Gene Rearrangement Positive
  • Ensartinib
  • Stanford, California
  • +3 more
Feb 15, 2022

NSCLC Trial in Shijiazhuang (Ensartinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Ensartinib
  • Shijiazhuang, Hebei, China
    Jun Feng Liu
Feb 6, 2022

NSCLC Trial in Guangzhou (Ensartinib, Bevacizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Aug 4, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 13, 2022

ALK-POSITIVE NSCLC Trial in Nanjing (Ensartinib)

Unknown status
  • ALK-POSITIVE NSCLC
  • Ensartinib
  • Nanjing, Jiangsu Provence, China
    Jiangsu Province Hospital Affiliated to Nanjing Madical Universi
Jan 14, 2019

Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial in Puerto

Recruiting
  • Malignant Solid Neoplasm
  • +26 more
  • Ensartinib
  • +2 more
  • Birmingham, Alabama
  • +121 more
Aug 24, 2022

NSCLC, Carcinoma, NSCLC Trial in New York (Ensartinib, Durvalumab)

Completed
  • Non-small Cell Lung Cancer
  • +2 more
  • New York, New York
    Research Facility
Oct 25, 2018

Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +44 more
  • Biopsy
  • +16 more
  • Birmingham, Alabama
  • +165 more
Aug 24, 2022